Dextrometorphan-quinidine for the treatment of pseudobulbar affect

Source:
Centre for Reviews and Dissemination Health Technology Assessments - CRD HTA
Publisher:
Centre for Reviews and Dissemination
Publication date:
25 November 2016

Abstract

Evidence of moderate quality shows that short-term use of dextrometorphan/quinidine would reduce the severity and number of weekly uncontrollable outbursts of laughing/crying in patients with pseudobulbar affect and diagnosed amyotrophic lateral sclerosis or multiple sclerosis when compared to placebo. Low-quality evidence suggests that its use would also benefit patients with pseudobulbar affect secondary to dementia, traumatic brain injury and stroke. The clinical practice guidelines that mention it, recommend it as a treatment option; it is covered by some United States health sponsorsXST: This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database